2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
33
Colorectal Neoplasms
12
Neoplasms
11
Pain, Postoperative
10
Lung Neoplasms
9
Brain Neoplasms
8
Stomach Neoplasms
7
Prostatic Neoplasms
7
Pancreatic Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Melanoma
6
Leukemia, Myeloid, Acute
5
Ovarian Neoplasms
4
Myoma
4
Lymphoma, Non-Hodgkin
4
Leiomyoma
4
Hemorrhage
4
Head and Neck Neoplasms
4
Glioblastoma
4
Colonic Neoplasms
4
Agnosia
4
Skin Neoplasms
3
Recurrence
3
Rectal Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neurotoxicity Syndromes
3
Neoplasm Metastasis
3
Nasopharyngeal Carcinoma
3
Myelodysplastic Syndromes
3
Multiple Endocrine Neoplasia Type 1
3
Interventions
resiniferatoxin
3
Ketamine
3
Morphine
2
Methadone
2
Dexmedetomidine
2
ziconotide
1
substance P-saporin
1
Standard of Care
1
Sodium Chloride
1
Ropivacaine
1
Registries
1
Pregabalin
1
Passive Cutaneous Anaphylaxis
1
Midazolam
1
Lidocaine
1
Infusion Pumps, Implantable
1
Hydromorphone
1
Fentanyl
1
Calcium Dobesilate
1
Acetaminophen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pain, Intractable
×
Sodium Chloride
×
Clear all
NCT01951911
2017-07-11
KETA-1
Haukeland University Hospital
Phase 3
Withdrawn